According to Longeveron's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 11.9575. At the end of 2023 the company had a P/S ratio of 48.2.
Year | P/S ratio | Change |
---|---|---|
2023 | 48.2 | -13.04% |
2022 | 55.4 | -71.26% |
2021 | 193 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |